Literature DB >> 21646483

Low fitness cost of the multidrug resistance gene cfr.

Jacqueline M LaMarre1, Jeffrey B Locke, Karen J Shaw, Alexander S Mankin.   

Abstract

The recently described rRNA methyltransferase Cfr that methylates the conserved 23S rRNA residue A2503, located in a functionally critical region of the ribosome, confers resistance to an array of ribosomal antibiotics, including linezolid. A number of reports of linezolid-resistant cfr-positive clinical strains indicate the possible rapid spread of this resistance mechanism. Since the rate of dissemination and the efficiency of maintenance of a resistance gene depend on the fitness cost associated with its acquisition, we investigated the fitness cost of cfr expression in a laboratory Staphylococcus aureus strain. We found that acquisition of the cfr gene does not produce any appreciable reduction in the cell growth rate. Only in a cogrowth competition experiment was some loss of fitness observed because Cfr-expressing cells slowly lose to the cfr-negative control strain. Interestingly, cells expressing wild-type and catalytically inactive Cfr had very similar growth characteristics, indicating that the slight fitness cost associated with cfr acquisition stems from expression of the Cfr polypeptide rather than from the modification of the conserved rRNA residue. In some clinical isolates, cfr is coexpressed with the erm gene, which encodes a methyltransferase targeting another 23S rRNA residue, A2058. Dimethylation of A2058 by Erm notably increases the fitness cost associated with the Cfr-mediated methylation of A2503. The generally low fitness cost of cfr acquisition observed in our experiments with the laboratory S. aureus strain offers a microbiological explanation for the apparent spread of the cfr gene among pathogens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21646483      PMCID: PMC3147626          DOI: 10.1128/AAC.00153-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.

Authors:  Miguel Sánchez García; María Angeles De la Torre; Gracia Morales; Beatriz Peláez; María José Tolón; Sara Domingo; Francisco Javier Candel; Raquel Andrade; Ana Arribi; Nicolás García; Fernando Martínez Sagasti; José Fereres; Juan Picazo
Journal:  JAMA       Date:  2010-06-09       Impact factor: 56.272

2.  Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain.

Authors:  Hector Bonilla; Michael D Huband; Joan Seidel; Helen Schmidt; Marykay Lescoe; Sandra P McCurdy; M Megan Lemmon; Lori A Brennan; A Tait-Kamradt; Laura Puzniak; John P Quinn
Journal:  Clin Infect Dis       Date:  2010-10-01       Impact factor: 9.079

3.  The key function of a conserved and modified rRNA residue in the ribosomal response to the nascent peptide.

Authors:  Nora Vázquez-Laslop; Haripriya Ramu; Dorota Klepacki; Krishna Kannan; Alexander S Mankin
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

4.  First report of Staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization.

Authors:  Rodrigo E Mendes; Lalitagauri Deshpande; Eduardo Rodriguez-Noriega; James E Ross; Ronald N Jones; Rayo Morfin-Otero
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

5.  RlmN and Cfr are radical SAM enzymes involved in methylation of ribosomal RNA.

Authors:  Feng Yan; Jacqueline M LaMarre; Rene Röhrich; Jochen Wiesner; Hassan Jomaa; Alexander S Mankin; Danica Galonić Fujimori
Journal:  J Am Chem Soc       Date:  2010-03-24       Impact factor: 15.419

Review 6.  Antibiotic resistance and its cost: is it possible to reverse resistance?

Authors:  Dan I Andersson; Diarmaid Hughes
Journal:  Nat Rev Microbiol       Date:  2010-03-08       Impact factor: 60.633

7.  Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use.

Authors:  M Sundqvist; P Geli; D I Andersson; M Sjölund-Karlsson; A Runehagen; H Cars; K Abelson-Storby; O Cars; G Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2009-11-08       Impact factor: 5.790

8.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

9.  Structural insight into nascent polypeptide chain-mediated translational stalling.

Authors:  Birgit Seidelt; C Axel Innis; Daniel N Wilson; Marco Gartmann; Jean-Paul Armache; Elizabeth Villa; Leonardo G Trabuco; Thomas Becker; Thorsten Mielke; Klaus Schulten; Thomas A Steitz; Roland Beckmann
Journal:  Science       Date:  2009-10-29       Impact factor: 47.728

10.  Insights into the structure, function and evolution of the radical-SAM 23S rRNA methyltransferase Cfr that confers antibiotic resistance in bacteria.

Authors:  Katarzyna H Kaminska; Elzbieta Purta; Lykke H Hansen; Janusz M Bujnicki; Birte Vester; Katherine S Long
Journal:  Nucleic Acids Res       Date:  2009-12-10       Impact factor: 16.971

View more
  22 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

3.  Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene.

Authors:  Jeffrey B Locke; Douglas E Zuill; Caitlyn R Scharn; Jennifer Deane; Daniel F Sahm; Gerald A Denys; Richard V Goering; Karen J Shaw
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

4.  Combined Effect of the Cfr Methyltransferase and Ribosomal Protein L3 Mutations on Resistance to Ribosome-Targeting Antibiotics.

Authors:  Kevin K Pakula; Lykke H Hansen; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 5.  Ribosome-targeting antibiotics and mechanisms of bacterial resistance.

Authors:  Daniel N Wilson
Journal:  Nat Rev Microbiol       Date:  2014-01       Impact factor: 60.633

6.  The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of Staphylococcus epidermidis isolate 426-3147L.

Authors:  Jacqueline LaMarre; Rodrigo E Mendes; Teresa Szal; Stefan Schwarz; Ronald N Jones; Alexander S Mankin
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

Review 7.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

8.  Fate of antimicrobial resistance genes in response to application of poultry and swine manure in simulated manure-soil microcosms and manure-pond microcosms.

Authors:  Mianzhi Wang; Yongxue Sun; Peng Liu; Jing Sun; Qin Zhou; Wenguang Xiong; Zhenling Zeng
Journal:  Environ Sci Pollut Res Int       Date:  2017-07-18       Impact factor: 4.223

9.  A high incidence and coexistence of multiresistance genes cfr and optrA among linezolid-resistant enterococci isolated from a teaching hospital in Wenzhou, China.

Authors:  Yizhi Zhang; Guofeng Dong; Jiahui Li; Lijiang Chen; Haiyang Liu; Wenzi Bi; Hong Lu; Tieli Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-16       Impact factor: 3.267

Review 10.  [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].

Authors:  Sandra Rincón; Diana Panesso; Lorena Díaz; Lina P Carvajal; Jinnethe Reyes; José M Munita; César A Arias
Journal:  Biomedica       Date:  2014-04       Impact factor: 0.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.